JPMorgan Chase & Co. set a GBX 5,500 ($73.54) price objective on AstraZeneca (LON:AZN) in a research note published on Thursday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
AZN has been the subject of several other reports. reaffirmed a reduce rating and set a GBX 4,100 ($54.82) price objective on shares of AstraZeneca in a research report on Monday, September 11th. Barclays reaffirmed an overweight rating and set a GBX 6,300 ($84.24) price objective on shares of AstraZeneca in a research report on Thursday, October 5th. BNP Paribas set a GBX 5,300 ($70.87) target price on AstraZeneca and gave the company a neutral rating in a research report on Monday, September 11th. UBS Group set a GBX 4,550 ($60.84) target price on AstraZeneca and gave the company a neutral rating in a research report on Monday, October 23rd. Finally, Shore Capital reissued a hold rating on shares of AstraZeneca in a research report on Monday, October 9th. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of GBX 5,200.82 ($69.54).
AstraZeneca (LON:AZN) traded up GBX 33 ($0.44) during trading hours on Thursday, hitting GBX 5,204 ($69.58). The stock had a trading volume of 1,470,592 shares, compared to its average volume of 1,720,000. The firm has a market cap of $65,700.00 and a PE ratio of 2,526.21. AstraZeneca has a twelve month low of GBX 4,136.50 ($55.31) and a twelve month high of GBX 5,520 ($73.81).
ILLEGAL ACTIVITY NOTICE: “AstraZeneca (AZN) Given a GBX 5,500 Price Target by JPMorgan Chase & Co. Analysts” was originally reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3127404/astrazeneca-azn-given-a-gbx-5500-price-target-by-jpmorgan-chase-co-analysts.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.